Alex Goldsmith joined Flagship Pioneering in 2017 as Principal to Noubar Afeyan, the firm’s CEO. Since 2020 he has focused exclusively on company creation, and currently forms part of the Origination team led by Lovisa Afzelius. His particular interests include the development and application of new technologies and biological insights in the context of disease prediction, prevention and mitigation.
Alex joined Flagship from Pfizer, where he served in several positions within the company’s Worldwide R&D organization. Most recently, he was head of business operations and strategy for the Medicinal Sciences division, a large and complex unit responsible for the design, development, and early manufacturing of small molecules, biologics, and vaccines. Immediately before joining Pfizer, Alex worked at The Boston Consulting Group, where he advised clients on strategic and operational issues across a range of industries.
Alex holds a Ph.D. in neurobiology from the University of Cambridge and an undergraduate degree (First Class Honours) in molecular and cellular biochemistry from Oxford University.